Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Tuesday, February 14, 2017 3:46:25 PM
Health care services provider GreeneStone Healthcare Corporation (OTCQB: GRST) today announced a string of strategic moves designed to strengthen the company’s balance sheet and position it for sustainable growth in the U.S. health care market. First, GreeneStone acquired Cranberry Cove Holdings, which owns the real estate used by GreeneStone’s addiction treatment facility in Muskoka, Ontario. Next, the company sold the operational assets of its Muskoka clinic for a total consideration of CDN$10 million. Through its newly-acquired subsidiary, the company will continue to own and lease the clinic building moving forward. Finally, on February 13, 2017, GreeneStone closed on the acquisition of the business and real estate assets of Seastone addiction treatment center in Delray Beach, Florida. Shawn Leon, president and CEO of GreeneStone, noted the benefits of these strategic moves in the news release. “We have been able to eliminate debt that was accumulated during the building of the Canadian business in 2012 and 2013, and we will benefit from a stable cash flow generated by rental income from the lease of the Muskoka clinic while we build the business in Florida,” he stated.
To view the full press release, visit http://nnw.fm/yBN3s
About GreeneStone Healthcare Corporation
GreeneStone Healthcare Corporation (OTCQB: GRST) operates in the behavioral healthcare space, specifically in the treatment of substance use disorders. GreeneStone developed a unique style of treatment over the last six years and has had much success with in-patient treatment for adults. Greenestone will continue to develop its programs with its expansion into the United States. For more information, you can visit our website at www.greenestoneclinic.com and www.greenestone.net.
Recent GRST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:54:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:55:26 PM
- Form 1-A POS - • Edgar (US Regulatory) • 10/20/2023 07:29:40 PM
- Form 1-A POS - • Edgar (US Regulatory) • 08/29/2023 07:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:37:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 12:43:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 04:51:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 06:56:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM